Telomir Pharmaceuticals, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| – | – | – | – | – | |
| – | – | – | +169.2% | – | |
| – | – | – | – | -23.0% | |
| – | +1,957.6% | -70.5% | +11.1% | +370.2% | |
| – | -100.0% | – | -100.0% | – | |
| – | – | +214.1% | -107.0% | – | |
| – | +293.7% | +721.1% | +64.1% | +53.2% | |
| – | – | -113.2% | – | +376.0% | |
| – | – | – | – | – |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.